Preoperative Corticosteroids Reduce Diagnostic Accuracy of Stereotactic Biopsies in Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis
- PMID: 38865324
- DOI: 10.1227/neu.0000000000002944
Preoperative Corticosteroids Reduce Diagnostic Accuracy of Stereotactic Biopsies in Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis
Abstract
Background and objectives: Despite general acceptance that corticosteroid therapy (CST) should be withheld before biopsy for suspected primary central nervous system lymphoma (PCNSL), there remains conflicting evidence surrounding the precise impact of preoperative CST on the histopathological diagnosis. The objective of this systematic review and meta-analysis was to describe and quantify the effects of preoperative CST on the diagnostic accuracy of biopsies for PCNSL.
Methods: Primary articles were screened from Ovid MEDLINE, Embase, Web of Science, and Scopus databases. Meta-analysis was performed for immunocompetent patients with histologically confirmed PCNSL. Subgroup and regression analyses were performed to assess the effects of biopsy type, CST duration, dose, and preoperative taper on the diagnostic accuracy. In addition, the sensitivity of cerebrospinal fluid (CSF) analyses for PCNSL was assessed.
Results: Nineteen studies, comprising 1226 patients (45% female; mean age: 60.3 years), were included. Preoperative CST increased the risk of nondiagnostic biopsy with a relative risk (RR) of 2.1 (95% CI: 1.1-4.1). In the stereotactic biopsy subgroup, the RR for nondiagnostic biopsy was 3.0 (95% CI: 1.2-7.5). CST taper, duration, and dose did not significantly influence diagnostic biopsy rates. The sensitivity of CSF cytology, including flow cytometry, for PCNSL was 8.0% (95% CI: 6.0%-10.7%).
Conclusion: Our results suggest that preoperative CST reduces the diagnostic yield of stereotactic biopsies for PCNSL. We found no evidence that tapering CST before biopsy improves diagnostic rates. CSF analysis currently has a poor sensitivity for the diagnosis of PCNSL.
Copyright © Congress of Neurological Surgeons 2024. All rights reserved.
Similar articles
-
Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).Cochrane Database Syst Rev. 2012 Nov 14;11:CD009355. doi: 10.1002/14651858.CD009355.pub2. Cochrane Database Syst Rev. 2012. PMID: 23152274
-
Screening for prostate cancer.Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD004720. doi: 10.1002/14651858.CD004720.pub3. Cochrane Database Syst Rev. 2013. PMID: 23440794 Free PMC article.
-
The role of additional radiotherapy for primary central nervous system lymphoma.Cochrane Database Syst Rev. 2014 Jun 16;2014(6):CD009211. doi: 10.1002/14651858.CD009211.pub2. Cochrane Database Syst Rev. 2014. PMID: 24931518 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Diagnostics and treatment delay in primary central nervous system lymphoma: What the neurosurgeon should know.Acta Neurochir (Wien). 2024 Jun 11;166(1):261. doi: 10.1007/s00701-024-06138-3. Acta Neurochir (Wien). 2024. PMID: 38858236 Free PMC article. Review.
Cited by
-
Case Report: Clinical response of ensartinib for inflammatory myofibroblastic tumor of the urinary bladder with multiple metastases and TPM4-ALK fusion.Front Oncol. 2025 May 2;15:1481602. doi: 10.3389/fonc.2025.1481602. eCollection 2025. Front Oncol. 2025. PMID: 40386559 Free PMC article.
References
-
- Lv C, Wang J, Zhou M, Xu JY, Chen B, Wan Y. Primary central nervous system lymphoma in the United States, 1975-2017. Ther Adv Hematol. 2022;13:20406207211066166.
-
- O’Neill BP, Decker PA, Tieu C, Cerhan JR. The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin’s lymphoma. Am J Hematol. 2013;88(12):997-1000.
-
- Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105(9):1414-1418.
-
- Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35(21):2410-2418.
-
- Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical